Child and Adolescent Registry for Participants With Narcolepsy
Launched by JAZZ PHARMACEUTICALS · May 21, 2021
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The CATNAP trial is a study that aims to learn more about narcolepsy in children and teenagers. Narcolepsy is a condition that affects sleep, causing excessive daytime sleepiness and sudden sleep attacks. This registry will collect information to help researchers understand how narcolepsy affects young people over time. The study is open to any child or adolescent under 18 years old who has been diagnosed with narcolepsy by a doctor. Participants will need to be comfortable completing the necessary consent forms and participating in English.
If you or someone you know meets these criteria, you can expect to be part of a larger effort to gather important information about narcolepsy in young patients. The study is currently recruiting participants from 16 active clinical sites and also offers a virtual option, making it easier for people across the United States to join. For more details or to enroll, you can visit the CATNAP website or reach out via email. This is a great opportunity to contribute to research that may improve the understanding and treatment of narcolepsy in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any child or adolescent with a physician-confirmed diagnosis of narcolepsy
- • Age less than 18 years
- • Willing to participate in the Registry and complete the informed consent form
- • Able to participate in English based registry
- Exclusion Criteria:
- • Age 18 years or more
- • Fail to complete the informed consent form
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to identifying, developing, and commercializing innovative therapies that address unmet medical needs in various therapeutic areas, including sleep disorders, neurology, and hematology. With a strong commitment to advancing patient care, Jazz Pharmaceuticals leverages cutting-edge research and development to deliver transformative medicines that improve the quality of life for patients. The company emphasizes collaboration and integrity in its clinical trials, striving to ensure robust scientific rigor and ethical standards throughout its research endeavors. Through its innovative approaches and patient-centric focus, Jazz Pharmaceuticals aims to make a meaningful impact in the lives of those it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Tampa, Florida, United States
Philadelphia, Pennsylvania, United States
Baltimore, Maryland, United States
Kansas City, Missouri, United States
Norfolk, Virginia, United States
Phoenix, Arizona, United States
Cincinnati, Ohio, United States
Washington, District Of Columbia, United States
Tucson, Arizona, United States
Columbus, Ohio, United States
Tampa, Florida, United States
Chesterfield, Missouri, United States
Boston, Massachusetts, United States
Tampa, Florida, United States
Dublin, Ohio, United States
Houston, Texas, United States
San Diego, California, United States
Fayetteville, Arkansas, United States
Tucson, Arizona, United States
Chicago, Illinois, United States
Washington, District Of Columbia, United States
Danville, Pennsylvania, United States
Redwood City, California, United States
Manhasset, New York, United States
Little Rock, Arkansas, United States
Grand Rapids, Michigan, United States
Cleveland, Ohio, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials